{
    "name": "acetazolamide",
    "comment": "Rx",
    "other_names": [
        "Diamox Sequels (DSC)"
    ],
    "classes": [
        "Anticonvulsants",
        "Other",
        "Antiglaucoma",
        "Carbonic Anhydrase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/acetazolamide-342809",
    "pregnancy": {
        "common": [
            "Pregnancy category: C",
            "Lactation: Enters breast milk; not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Enters breast milk; not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypokalemia",
                "Hyponatremia",
                "Hyperchloremic acidosis",
                "Hypersensitivity to acetazolamide or sulfa",
                "Liver disease",
                " Severe renal disease or dysfunction",
                "Long term use in noncongestive angle-closure glaucoma",
                "Cirrhosis",
                "Long-term administration in patients with chronic, noncongestive angle-closure glaucoma"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in COPD, emphysema, and concomitant high-dose aspirin",
                "Use caution in diabetes, respiratory acidosis, and hepatic impairment",
                "Adverse drug reactions common to sulfonamide derivatives; Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) may occur",
                "May impair alertness and/or physical coordination",
                "FDA-approved product labeling for many medications have included a broad contraindication in patients with a prior allregic reaction to sulfonamides; however, recent studies have suggested that crossreactivity between antibiotic sulfonamides and nonantibiotic sulfonamides is unlikely to occur",
                "May impair alertness and/or physical coordination",
                "Severe adverse effects including tachypnea, anorexia, coma, lethargy, and death reported with high-dose aspirin; use caution or avoid administration",
                "Increasing dose does not increase diuresis; may instead increase the incidence of paresthesia and/or drowsiness",
                "IM administration not recommended due to alkaline pH, which may cause pain"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "methenamine",
            "description": {
                "common": "acetazolamide, methenamine. Other (see comment). Contraindicated. \nComment: This combination may form an insoluble precipitate in the urine, decreasing the effects of both agents."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "acetazolamide and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "acetazolamide will decrease the level or effect of amantadine by  Other (see comment). Modify Therapy/Monitor Closely. Excretion rate of amantadine increases rapidly when urine is acidic, administration of urine acidifying drugs may increase elimination of amantadine from the body. Monitor for efficacy of amantadine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "acetazolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "acetazolamide, aspirin rectal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "acetazolamide, aspirin/citric acid/sodium bicarbonate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of acetazolamide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "balsalazide",
            "description": {
                "common": "acetazolamide, balsalazide.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bearberry",
            "description": {
                "common": "acetazolamide will increase the level or effect of bearberry by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of benzphetamine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "acetazolamide, choline magnesium trisalicylate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of crizotinib by  aldehyde dehydrogenase inhibition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "acetazolamide and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "acetazolamide and deutetrabenazine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of dextroamphetamine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and acetazolamide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and acetazolamide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "acetazolamide, diflunisal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ephedrine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, acetazolamide.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "acetazolamide will increase the level or effect of flecainide by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of lisdexamfetamine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone increases effects of acetazolamide by Other (see comment). Use Caution/Monitor. \nComment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "memantine",
            "description": {
                "common": "acetazolamide will increase the level or effect of memantine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "acetazolamide, mesalamine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "acetazolamide increases toxicity of metformin by Other (see comment). Use Caution/Monitor. \nComment: Decreases serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate transdermal",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of acetazolamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "acetazolamide will increase the level or effect of mexiletine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitazoxanide",
            "description": {
                "common": "nitazoxanide, acetazolamide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, acetazolamide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat decreases levels of acetazolamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "acetazolamide, ospemifene.\nEither increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "acetazolamide will increase the level or effect of pseudoephedrine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "acetazolamide will increase the level or effect of quinidine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "acetazolamide, salicylates (non-asa).\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "acetazolamide, salsalate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevelamer",
            "description": {
                "common": "sevelamer decreases levels of acetazolamide by increasing elimination. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "acetazolamide, sulfasalazine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of acetazolamide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate, acetazolamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of kidney stone formation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trientine",
            "description": {
                "common": "acetazolamide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "willow bark",
            "description": {
                "common": "acetazolamide, willow bark.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "acetazolamide will increase the level or effect of abemaciclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "abiraterone",
            "description": {
                "common": "acetazolamide will increase the level or effect of abiraterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of acalabrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "acetazolamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "acetazolamide decreases levels of acetaminophen IV by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "acetazolamide decreases levels of acetaminophen rectal by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ado-trastuzumab emtansine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfentanil",
            "description": {
                "common": "acetazolamide will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "acetazolamide will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alpelisib",
            "description": {
                "common": "acetazolamide will increase the level or effect of alpelisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alprazolam",
            "description": {
                "common": "acetazolamide will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ambrisentan",
            "description": {
                "common": "acetazolamide will increase the level or effect of ambrisentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiodarone",
            "description": {
                "common": "acetazolamide will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "acetazolamide, amobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "apalutamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of apalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "apixaban",
            "description": {
                "common": "acetazolamide will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "apomorphine",
            "description": {
                "common": "acetazolamide will increase the level or effect of apomorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "apremilast",
            "description": {
                "common": "acetazolamide will decrease the level or effect of apremilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aprepitant",
            "description": {
                "common": "acetazolamide will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "acetazolamide will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "acetazolamide will decrease the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin will decrease the level or effect of acetazolamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "astemizole",
            "description": {
                "common": "acetazolamide will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atazanavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atogepant",
            "description": {
                "common": "acetazolamide will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "acetazolamide will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atracurium",
            "description": {
                "common": "acetazolamide decreases effects of atracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "avanafil",
            "description": {
                "common": "acetazolamide will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "avapritinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "avatrombopag",
            "description": {
                "common": "acetazolamide will increase the level or effect of avatrombopag by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "axitinib",
            "description": {
                "common": "acetazolamide increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "acetazolamide will increase the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "acetazolamide will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of benzphetamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "biotin",
            "description": {
                "common": "acetazolamide decreases levels of biotin by unspecified interaction mechanism. Minor/Significance Unknown. Biotin supplementation may be necessary."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bortezomib",
            "description": {
                "common": "acetazolamide will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "acetazolamide will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosutinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of bosutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brentuximab vedotin",
            "description": {
                "common": "acetazolamide will increase the level or effect of brentuximab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brigatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of brigatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "acetazolamide will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "acetazolamide will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "acetazolamide will increase the level or effect of buprenorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "acetazolamide will increase the level or effect of buprenorphine transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buspirone",
            "description": {
                "common": "acetazolamide will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "busulfan",
            "description": {
                "common": "acetazolamide will increase the level or effect of busulfan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "acetazolamide, butabarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "acetazolamide, butalbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcifediol",
            "description": {
                "common": "acetazolamide will increase the level or effect of calcifediol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcitriol",
            "description": {
                "common": "acetazolamide will increase the level or effect of calcitriol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "capmatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "acetazolamide will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cariprazine",
            "description": {
                "common": "acetazolamide will increase the level or effect of cariprazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "acetazolamide will increase the level or effect of chlordiazepoxide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "acetazolamide will increase the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "acetazolamide will increase the level or effect of chlorpheniramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ciclesonide inhaled",
            "description": {
                "common": "acetazolamide will increase the level or effect of ciclesonide inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cilostazol",
            "description": {
                "common": "acetazolamide will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cisapride",
            "description": {
                "common": "acetazolamide will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "acetazolamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "citalopram",
            "description": {
                "common": "acetazolamide will increase the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "acetazolamide will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "acetazolamide will increase the level or effect of clonazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clorazepate",
            "description": {
                "common": "acetazolamide will increase the level or effect of clorazepate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cobicistat",
            "description": {
                "common": "acetazolamide will increase the level or effect of cobicistat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cobimetinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "acetazolamide will increase the level or effect of cocaine topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colchicine",
            "description": {
                "common": "acetazolamide will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "conivaptan",
            "description": {
                "common": "acetazolamide will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "acetazolamide will increase the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "copanlisib",
            "description": {
                "common": "acetazolamide will increase the level or effect of copanlisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyanocobalamin",
            "description": {
                "common": "acetazolamide decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of cyclophosphamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "acetazolamide will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of dabrafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "daclatasvir",
            "description": {
                "common": "acetazolamide will increase the level or effect of daclatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dantrolene",
            "description": {
                "common": "acetazolamide will increase the level or effect of dantrolene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dapsone",
            "description": {
                "common": "acetazolamide will increase the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "darifenacin",
            "description": {
                "common": "acetazolamide will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "darunavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dasatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "acetazolamide will increase the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "delavirdine",
            "description": {
                "common": "acetazolamide will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "acetazolamide will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of dexlansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "dexmethylphenidate increases effects of acetazolamide by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "acetazolamide increases levels of dextroamphetamine by passive renal tubular reabsorption due to increased pH. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "acetazolamide will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "acetazolamide will increase the level or effect of diazepam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "acetazolamide will increase the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "acetazolamide will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "disopyramide",
            "description": {
                "common": "acetazolamide will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "docetaxel",
            "description": {
                "common": "acetazolamide will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doravirine",
            "description": {
                "common": "acetazolamide will increase the level or effect of doravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxepin cream",
            "description": {
                "common": "acetazolamide will increase the level or effect of doxepin cream by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "acetazolamide will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "acetazolamide will increase the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dronabinol",
            "description": {
                "common": "acetazolamide will increase the level or effect of dronabinol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dronedarone",
            "description": {
                "common": "acetazolamide will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "duvelisib",
            "description": {
                "common": "acetazolamide will increase the level or effect of duvelisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "efavirenz",
            "description": {
                "common": "acetazolamide will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "elagolix",
            "description": {
                "common": "acetazolamide will increase the level or effect of elagolix by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "acetazolamide will increase the level or effect of elbasvir/grazoprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eletriptan",
            "description": {
                "common": "acetazolamide will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eliglustat",
            "description": {
                "common": "acetazolamide will increase the level or effect of eliglustat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "elvitegravir",
            "description": {
                "common": "acetazolamide will increase the level or effect of elvitegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "acetazolamide will increase the level or effect of elvitegravir/cobicistat/emtricitabine/tenofovir DF by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encorafenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of encorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enfortumab vedotin",
            "description": {
                "common": "acetazolamide will increase the level or effect of enfortumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "entrectinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of entrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "acetazolamide will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "acetazolamide will increase the level or effect of ergoloid mesylates by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ergonovine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ergonovine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ergotamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erlotinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "acetazolamide will increase the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "acetazolamide will increase the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "acetazolamide will increase the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "acetazolamide will increase the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "escitalopram",
            "description": {
                "common": "acetazolamide will increase the level or effect of escitalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of esomeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estradiol",
            "description": {
                "common": "acetazolamide will increase the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "acetazolamide will increase the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estrogens esterified",
            "description": {
                "common": "acetazolamide will increase the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estropipate",
            "description": {
                "common": "acetazolamide will increase the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eszopiclone",
            "description": {
                "common": "acetazolamide will increase the level or effect of eszopiclone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "acetazolamide will increase the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "acetazolamide will increase the level or effect of ethosuximide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "acetazolamide, ethotoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etoposide",
            "description": {
                "common": "acetazolamide will increase the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etravirine",
            "description": {
                "common": "acetazolamide will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "everolimus",
            "description": {
                "common": "acetazolamide will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "exemestane",
            "description": {
                "common": "acetazolamide will increase the level or effect of exemestane by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fedratinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of fedratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "acetazolamide will increase the level or effect of felbamate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "acetazolamide will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "acetazolamide will increase the level or effect of fenofibrate micronized by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "acetazolamide will increase the level or effect of fenofibric acid by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fentanyl",
            "description": {
                "common": "acetazolamide will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "acetazolamide will increase the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "acetazolamide will increase the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "acetazolamide will increase the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "finerenone",
            "description": {
                "common": "acetazolamide will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flibanserin",
            "description": {
                "common": "acetazolamide will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flunisolide inhaled",
            "description": {
                "common": "acetazolamide will increase the level or effect of flunisolide inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurazepam",
            "description": {
                "common": "acetazolamide will increase the level or effect of flurazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flutamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of flutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluticasone furoate",
            "description": {
                "common": "acetazolamide will increase the level or effect of fluticasone furoate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluticasone inhaled",
            "description": {
                "common": "acetazolamide will increase the level or effect of fluticasone inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "acetazolamide will increase the level or effect of fosaprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "acetazolamide, fosphenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of fostamatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gefitinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of gefitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glasdegib",
            "description": {
                "common": "acetazolamide will increase the level or effect of glasdegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "acetazolamide will increase the level or effect of glecaprevir/pibrentasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "guanfacine",
            "description": {
                "common": "acetazolamide will increase the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "haloperidol",
            "description": {
                "common": "acetazolamide will increase the level or effect of haloperidol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "acetazolamide will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydroxyprogesterone caproate (DSC)",
            "description": {
                "common": "acetazolamide will increase the level or effect of hydroxyprogesterone caproate (DSC) by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ibrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "idelalisib",
            "description": {
                "common": "acetazolamide will increase the level or effect of idelalisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of ifosfamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "acetazolamide decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indinavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan",
            "description": {
                "common": "acetazolamide will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "acetazolamide will increase the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "acetazolamide will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isosorbide dinitrate",
            "description": {
                "common": "acetazolamide will increase the level or effect of isosorbide dinitrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isosorbide mononitrate",
            "description": {
                "common": "acetazolamide will increase the level or effect of isosorbide mononitrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "istradefylline",
            "description": {
                "common": "acetazolamide will increase the level or effect of istradefylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "itraconazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "acetazolamide increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ivosidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ixabepilone",
            "description": {
                "common": "acetazolamide will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ixazomib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ixazomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketamine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ketamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lacosamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of lacosamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lapatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of larotrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lemborexant",
            "description": {
                "common": "acetazolamide will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levamlodipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of levamlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levocarnitine",
            "description": {
                "common": "acetazolamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "acetazolamide will increase the level or effect of levomilnacipran by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "acetazolamide will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "acetazolamide will increase the level or effect of levonorgestrel oral by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "linagliptin",
            "description": {
                "common": "acetazolamide will increase the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lomitapide",
            "description": {
                "common": "acetazolamide increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "acetazolamide will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lopinavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of lorlatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "losartan",
            "description": {
                "common": "acetazolamide will increase the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lovastatin",
            "description": {
                "common": "acetazolamide will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "acetazolamide will increase the level or effect of lumacaftor/ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "acetazolamide will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lurasidone",
            "description": {
                "common": "acetazolamide will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "macimorelin",
            "description": {
                "common": "acetazolamide will increase the level or effect of macimorelin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maraviroc",
            "description": {
                "common": "acetazolamide will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "marijuana",
            "description": {
                "common": "acetazolamide will increase the level or effect of marijuana by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "acetazolamide will increase the level or effect of medroxyprogesterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mefloquine",
            "description": {
                "common": "acetazolamide will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mestranol",
            "description": {
                "common": "acetazolamide will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metaxalone",
            "description": {
                "common": "acetazolamide will increase the level or effect of metaxalone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methadone",
            "description": {
                "common": "acetazolamide will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "acetazolamide will increase the level or effect of methylergonovine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "acetazolamide will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miconazole oral",
            "description": {
                "common": "acetazolamide will increase the level or effect of miconazole oral by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midazolam",
            "description": {
                "common": "acetazolamide will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "acetazolamide will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midostaurin",
            "description": {
                "common": "acetazolamide will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mifepristone",
            "description": {
                "common": "acetazolamide will increase the level or effect of mifepristone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "acetazolamide will increase the level or effect of mirtazapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "modafinil",
            "description": {
                "common": "acetazolamide will increase the level or effect of modafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "montelukast",
            "description": {
                "common": "acetazolamide will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naldemedine",
            "description": {
                "common": "acetazolamide will increase the level or effect of naldemedine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naloxegol",
            "description": {
                "common": "acetazolamide will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nefazodone",
            "description": {
                "common": "acetazolamide will increase the level or effect of nefazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "acetazolamide will increase the level or effect of netupitant/palonosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nevirapine",
            "description": {
                "common": "acetazolamide will increase the level or effect of nevirapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nilotinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nimodipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "acetazolamide will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "norethindrone",
            "description": {
                "common": "acetazolamide will increase the level or effect of norethindrone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "norgestrel",
            "description": {
                "common": "acetazolamide will increase the level or effect of norgestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "olaparib",
            "description": {
                "common": "acetazolamide will increase the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of ombitasvir/paritaprevir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "acetazolamide will increase the level or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "omeprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of omeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "acetazolamide decreases effects of onabotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ondansetron",
            "description": {
                "common": "acetazolamide will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "acetazolamide will increase the level or effect of osilodrostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "osimertinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of osimertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ospemifene",
            "description": {
                "common": "acetazolamide will increase the level or effect of ospemifene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxycodone",
            "description": {
                "common": "acetazolamide will increase the level or effect of oxycodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "acetazolamide will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "acetazolamide will increase the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "palbociclib",
            "description": {
                "common": "acetazolamide will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pancuronium",
            "description": {
                "common": "acetazolamide decreases effects of pancuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "panobinostat",
            "description": {
                "common": "acetazolamide will increase the level or effect of panobinostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paricalcitol",
            "description": {
                "common": "acetazolamide will increase the level or effect of paricalcitol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pazopanib",
            "description": {
                "common": "acetazolamide will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "acetazolamide, pentobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perampanel",
            "description": {
                "common": "acetazolamide will increase the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of pexidartinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "acetazolamide, phenobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "acetazolamide, phenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "acetazolamide will increase the level or effect of pimavanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pimozide",
            "description": {
                "common": "acetazolamide will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pitolisant",
            "description": {
                "common": "acetazolamide will increase the level or effect of pitolisant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "polatuzumab vedotin",
            "description": {
                "common": "acetazolamide will increase the level or effect of polatuzumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "acetazolamide will increase the level or effect of pomalidomide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ponatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ponatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "praziquantel",
            "description": {
                "common": "acetazolamide will increase the level or effect of praziquantel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primaquine",
            "description": {
                "common": "acetazolamide will increase the level or effect of primaquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "acetazolamide decreases levels of primidone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "acetazolamide will increase the level or effect of progesterone intravaginal gel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "acetazolamide will increase the level or effect of progesterone micronized by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "progesterone, natural",
            "description": {
                "common": "acetazolamide will increase the level or effect of progesterone, natural by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quazepam",
            "description": {
                "common": "acetazolamide will increase the level or effect of quazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quetiapine",
            "description": {
                "common": "acetazolamide will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinidine",
            "description": {
                "common": "acetazolamide will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinine",
            "description": {
                "common": "acetazolamide will increase the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ranolazine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "acetazolamide decreases effects of rapacuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "regorafenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of regorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "acetazolamide will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ribociclib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ribociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rifabutin",
            "description": {
                "common": "acetazolamide will increase the level or effect of rifabutin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rimabotulinumtoxinB",
            "description": {
                "common": "acetazolamide decreases effects of rimabotulinumtoxinB by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rimegepant",
            "description": {
                "common": "acetazolamide will increase the level or effect of rimegepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "riociguat",
            "description": {
                "common": "acetazolamide will increase the level or effect of riociguat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ritonavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "acetazolamide will increase the level or effect of rivaroxaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rocuronium",
            "description": {
                "common": "acetazolamide decreases effects of rocuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "roflumilast",
            "description": {
                "common": "acetazolamide will increase the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rolapitant",
            "description": {
                "common": "acetazolamide will increase the level or effect of rolapitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "romidepsin",
            "description": {
                "common": "acetazolamide will increase the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ropivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "acetazolamide will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sage",
            "description": {
                "common": "sage decreases effects of acetazolamide by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction; some species of sage may cause convulsions."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salmeterol",
            "description": {
                "common": "acetazolamide will increase the level or effect of salmeterol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saquinavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "acetazolamide will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "acetazolamide, secobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of selpercatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "serdexmethylphenidate/dexmethylphenidate increases effects of acetazolamide by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sildenafil",
            "description": {
                "common": "acetazolamide will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "simvastatin",
            "description": {
                "common": "acetazolamide will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "siponimod",
            "description": {
                "common": "acetazolamide will increase the level or effect of siponimod by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sirolimus",
            "description": {
                "common": "acetazolamide will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "acetazolamide will increase the level or effect of sofosbuvir/velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "solifenacin",
            "description": {
                "common": "acetazolamide will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sonidegib",
            "description": {
                "common": "acetazolamide will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sorafenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of sorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "stiripentol",
            "description": {
                "common": "acetazolamide will increase the level or effect of stiripentol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "acetazolamide decreases effects of succinylcholine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sufentanil",
            "description": {
                "common": "acetazolamide will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "acetazolamide will increase the level or effect of sufentanil SL by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sunitinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "suvorexant",
            "description": {
                "common": "acetazolamide will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "acetazolamide will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus ointment",
            "description": {
                "common": "acetazolamide will increase the level or effect of tacrolimus ointment by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tadalafil",
            "description": {
                "common": "acetazolamide will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "acetazolamide decreases effects of tamoxifen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "acetazolamide will increase the level or effect of tamsulosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tasimelteon",
            "description": {
                "common": "acetazolamide will increase the level or effect of tasimelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "acetazolamide will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "acetazolamide will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "teniposide",
            "description": {
                "common": "acetazolamide will increase the level or effect of teniposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetracycline",
            "description": {
                "common": "acetazolamide will increase the level or effect of tetracycline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tezacaftor",
            "description": {
                "common": "acetazolamide will increase the level or effect of tezacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "theophylline",
            "description": {
                "common": "acetazolamide will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "acetazolamide will increase the level or effect of tiagabine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "acetazolamide will increase the level or effect of ticagrelor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "acetazolamide will increase the level or effect of ticlopidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tinidazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tipranavir",
            "description": {
                "common": "acetazolamide will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of tofacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolterodine",
            "description": {
                "common": "acetazolamide will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "acetazolamide will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "toremifene",
            "description": {
                "common": "acetazolamide will increase the level or effect of toremifene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trabectedin",
            "description": {
                "common": "acetazolamide will increase the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tramadol",
            "description": {
                "common": "acetazolamide will increase the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "acetazolamide will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triazolam",
            "description": {
                "common": "acetazolamide will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "acetazolamide will increase the level or effect of trimethoprim by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimipramine",
            "description": {
                "common": "acetazolamide will increase the level or effect of trimipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ubrogepant",
            "description": {
                "common": "acetazolamide will increase the level or effect of ubrogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ulipristal",
            "description": {
                "common": "acetazolamide will increase the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "acetazolamide will increase the level or effect of umeclidinium bromide/vilanterol inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of upadacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valbenazine",
            "description": {
                "common": "acetazolamide will increase the level or effect of valbenazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vandetanib",
            "description": {
                "common": "acetazolamide will increase the level or effect of vandetanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vardenafil",
            "description": {
                "common": "acetazolamide will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vecuronium",
            "description": {
                "common": "acetazolamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "velpatasvir",
            "description": {
                "common": "acetazolamide will increase the level or effect of velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "acetazolamide will increase the level or effect of vemurafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "venetoclax",
            "description": {
                "common": "acetazolamide will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "acetazolamide will increase the level or effect of venlafaxine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "acetazolamide will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "acetazolamide will increase the level or effect of vilanterol/fluticasone furoate inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vilazodone",
            "description": {
                "common": "acetazolamide will increase the level or effect of vilazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinblastine",
            "description": {
                "common": "acetazolamide will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine",
            "description": {
                "common": "acetazolamide will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "acetazolamide will increase the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "acetazolamide will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "acetazolamide will increase the level or effect of vorapaxar by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voriconazole",
            "description": {
                "common": "acetazolamide will increase the level or effect of voriconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "acetazolamide will increase the level or effect of vortioxetine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voxilaprevir",
            "description": {
                "common": "acetazolamide will increase the level or effect of voxilaprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "warfarin",
            "description": {
                "common": "warfarin will decrease the level or effect of acetazolamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "acetazolamide will increase the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zolpidem",
            "description": {
                "common": "acetazolamide will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Convulsions",
            "percent": null
        },
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "Flaccid paralysis",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Paresthesias",
            "percent": null
        },
        {
            "name": "Photosensitivity",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Metallic taste",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Hepatic disease",
            "percent": null
        },
        {
            "name": "Aplastic anemia",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Thrombocytopenic purpura",
            "percent": null
        },
        {
            "name": "Melena",
            "percent": null
        },
        {
            "name": "Acidosis",
            "percent": null
        },
        {
            "name": "Electrolyte imbalance",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "Polyuria",
            "percent": null
        },
        {
            "name": "Glycosuria",
            "percent": null
        },
        {
            "name": "Hearing dysfunction or tinnitus",
            "percent": null
        },
        {
            "name": "Sulfonamide type reactions",
            "percent": null
        }
    ]
}